Loading clinical trials...
Loading clinical trials...
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Amgen
NCT06451770 · Hypercholesterolemia, Hypertriglyceridemia, and more
NCT07473960 · Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
NCT06062394 · Hypertension, Hyperlipidemias
NCT07230730 · Hyperlipidemia
NCT07334834 · Hyperlipidemia
Research Site
Birmingham, Alabama
Research Site
Little Rock, Arkansas
Research Site
Encinitas, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions